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Table 1
Cytoreductive
Response n (%)
No Cytoreductive
Response n (%)
n¼16 8 (50) 8 (50)
Alive at Day 100 5 (31) 6 (38)
Alive, Day 100 Not Reached 1 (25) 1 (25)
Alive, in remission 5 (31) 3 (19)
Alive, relapsed 0 (0) 1 (6)
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plerixafor as part of their mobilization regimen at CCHMC
between January 2011 and September 2013 was conducted.
All patients receiving at least one dose were included. Data
on the number of plerixafor doses administered, cells
collected, and adverse events related to plerixafor were
collected.
Results: Eleven patients received plerixafor during the
designated time period; 9/11 patients (81.8%) had relapsed
malignancies and 2/11 patients (18.2%) required 3 and 4
autologous stem cell transplants for brain tumors. The me-
dian age of patients receiving plerixafor was 6 years (range 3-
15 years). All patients were given 0.24 mg/kg of plerixafor
and the median number of plerixafor doses received was 3
(range 1-4 doses). Collection target was 1x106 of CD34+cells/
kg for each transplant. An adequate number of CD34+ cells
were obtained in 9 of 11 patients (81.8%). The median
number of CD34+ cells collected for patients who reached
collection goal was 5.7x 106/kg (range 1.3-12.4 x 106/kg). No
acute adverse events were noted to be attributable to pler-
ixafor administration.
Conclusion: Our ﬁndings suggest that plerixafor use in
children is safe and efﬁcacious for the mobilization of PBSCs
in children with relapsed malignancies or requiring stem
cells for multiple transplants.462
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Outcomes in patients with relapsed/refractory acute myeloid
leukemia or advancedmyelodysplastic syndromewith active
disease at the time of allogeneic hematopoietic stem cell
transplant (HSCT) are generally poor. Published data indicate
the purine analog clofarabine can be used for cytoreduction
in patients with active disease as a “bridge” to HSCT when
followed by a standard conditioning regimen.
At Weill Cornell Medical Center (WC) clofarabine has been
used in refractory patients as a bridge to HSCT since 2011.
While published studies transplanted patients at cytopenic
nadir following clofarabine therapy, WC transplanted pa-
tients without regard to cytoreductive response.
The purpose of this study was to retrospectively examine
survival following clofarabine therapy and to determine if
cytoreduction affects outcomes. Secondaryoutcomes included
cytoreduction (deﬁned as post-treatment cellularity<20% and
blasts <10%), relapse after transplant, and non-hematologic
toxicity.
The study included adult patients who received clofarabine
30 mg/m2/day IV x 5 days prior to HSCT between November
2011 and June 2013. Twenty-one patients received a clofar-
abine bridge; 18 (86%) proceeded to HCST. The three who did
not were septic at the scheduled time of transplant. Two
patients refused a day 14 bone marrow and were not eval-
uated for response. Both died post-transplant.
Of the evaluable 16 patients, 8 (50%) are alive and in remis-
sion at a median of 3 months (range 2-10). One is alive, but
relapsed. Overall, 5 patients (31%) relapsed. Of the 7 patients
who died after transplant, median overall survival was 94days (range 5-188). Causes of death included relapse, sepsis,
and engraftment failure.
Eight (50%) patients achieved the pre-deﬁned cytoreductive
response. Five are alive and in remission at a median of
5 months (range 3-10). See table 1.
Based on preliminary analysis, cytoreduction with a clofar-
abine bridge appears to positively affect outcomes of re-
fractory patients who proceed to HSCT.463
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Cyclophosphamide is a chemotherapeutic agent that may be
included in stem cell transplant preparative regimens.
Cyclophosphamide is a pro-drug that is converted to cyto-
toxic metabolites via multiple pathways of the cytochrome
P-450 enzyme system. The triazole antifungal agents may be
prescribed as fungal prophylaxis for stem cell transplant
patients. The triazole antifungals are inhibitors of some cy-
tochrome P-450 pathways that are utilized for cyclophos-
phamide conversion. Due to this drug interaction, some
transplant centers will substitute an alternate agent instead
of a triazole antifungal during cyclophosphamide therapy.
Adult data has demonstrated that there is no difference in
the AUC of the phosphoramide metabolite when given with
ﬂuconazole. The goal of this review is to examine if anti-
fungal drug interactions inﬂuence stem cell transplant sur-
vival or disease relapse. This is a single center, retrospective
review of 5 years of transplant outcomes for pediatric and
young adult patients diagnosed with a hematologic malig-
nancy that underwent hematopoietic stem cell transplant
and received cyclophosphamide as part of the transplant
preparative regimen. Outcomes measured were survival,
relapse or progressive disease and non-relapse mortality.
The medical charts of 25 patients with diagnoses of AML,
ALL, MDS and Lymphoma were reviewed. Outcomes were
stratiﬁed for voriconazole, ﬂuconazole and non-azole anti-
fungal patients. Survival results were 50% for voriconazole,
64% for ﬂuconazole and 33% for non-azole therapies. Relapse
or progressive disease rates were 16% for voriconazole, 18%
for ﬂuconazole and 33% for non-azole therapies. Non-relapse
mortality was 33% for voriconazole, 18% for ﬂuconazole and
33% for non-azole therapies. For azole versus non-azole
therapy relapse rates were 17% versus 33% respectively. In a
small cohort of pediatric and young adult patients, the
cytochrome P-450 interaction of azole antifungals and
cyclophosphamide does not appear to inﬂuence transplant
